6,764 Shares in Sanofi (NASDAQ:SNY) Acquired by Heritage Oak Wealth Advisors LLC

Heritage Oak Wealth Advisors LLC purchased a new position in shares of Sanofi (NASDAQ:SNY) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 6,764 shares of the company’s stock, valued at approximately $390,000.

Several other large investors have also recently modified their holdings of the business. Barrow Hanley Mewhinney & Strauss LLC raised its position in shares of Sanofi by 113.8% during the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after buying an additional 3,164,092 shares in the last quarter. Magnetar Financial LLC raised its holdings in shares of Sanofi by 1,153.1% during the 2nd quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company’s stock valued at $121,605,000 after buying an additional 2,306,286 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Sanofi by 19.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock worth $417,017,000 after buying an additional 1,370,232 shares during the last quarter. Mondrian Investment Partners LTD grew its position in Sanofi by 43.1% during the first quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock valued at $192,023,000 after acquiring an additional 1,190,141 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its stake in shares of Sanofi by 3,440.6% during the first quarter. BNP Paribas Financial Markets now owns 1,033,549 shares of the company’s stock worth $50,230,000 after acquiring an additional 1,004,358 shares in the last quarter. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Sanofi Stock Up 3.6 %

Shares of NASDAQ:SNY traded up $1.89 on Friday, hitting $53.94. 1,484,328 shares of the company traded hands, compared to its average volume of 2,024,538. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The company has a market cap of $136.87 billion, a PE ratio of 28.29, a PEG ratio of 1.40 and a beta of 0.60. Sanofi has a 52 week low of $42.63 and a 52 week high of $58.97. The stock has a 50 day simple moving average of $56.08 and a 200-day simple moving average of $51.67.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. The firm had revenue of $10.75 billion for the quarter, compared to the consensus estimate of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The company’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.95 earnings per share. As a group, research analysts expect that Sanofi will post 4.23 earnings per share for the current year.

Analyst Ratings Changes

SNY has been the topic of a number of research analyst reports. Argus boosted their price target on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th. Citigroup raised Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Finally, StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Monday, October 14th. Three analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.